They further recommend testing for specific gene fusions, RAS/RAS driver mutations, homologous repair (BRCA1, BRCA2, PALB2) and mismatch repair mutations (MLH1, MSH2, MSH6, PMS2), as well as tumor microsatellite instability and tumor mutational burden. This evidence concerns the gene BRCA1 and neoplasm.